Quest Diagnostics (DGX) Raises Quarterly Dividend 15.2% to $0.38; 2.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Quest Diagnostics (DGX) Raises Quarterly Dividend 15.2% to $0.38; 2.2% Yield
January 29, 2015 7:18 AM EST
Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.08, $0.04 better than the analyst estimate of $1.04. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.85 billion.
Quest Diagnostics sees FY2015 EPS of $4.70-$4.85, versus the consensus of $4.43. Revenues to increase approximately 2% to... More
January 29, 2015 7:14 AM EST
RedHill Biopharma (Nasdaq: RDHL) provided an update on the progress with the ongoing RHB-104 Phase III development program for the treatment of Crohn's disease. The Company, together with Quest Diagnostics (NYSE: DGX), recently concluded a pre-submission meeting with the FDA regarding the development path of a commercial companion diagnostic test for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease patients. Following the constructive FDA meeting, RedHill intends to initiate a study of approximately 40 Crohn's disease patients to assess the clinical utility of the companion... More
